DAYBUE - (200MG/1ML ; Solution)

Generic Name	TROFINETIDE	**Innovator**	Acadia Pharma
Dosage	200MG/1ML ; Solution	**Branded US Sales**	Less Than $1000 mn
Probable FTF	None	**Known Para IV Filers**	None
Other ANDA developers	More Than 5	**Tentative Approvals**	None
Final Approvals	None	**Generic Launches**	None
Indication	DAYBUE is indicated for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.